Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins University School of Medicine, Baltimore, Maryland.
JAMA Netw Open. 2022 Feb 1;5(2):e220181. doi: 10.1001/jamanetworkopen.2022.0181.
Antibiotic overuse in long-term care (LTC) is common, prompting calls for antibiotic stewardship programs (ASPs) designed for specific use in these settings. The optimal approach to establish robust, sustainable ASPs in LTC facilities is unknown.
To determine if the Agency for Healthcare Research and Quality (AHRQ) Safety Program for Improving Antibiotic Use, an educational initiative to establish ASPs focusing on patient safety, is associated with reductions in antibiotic use in LTC settings.
DESIGN, SETTING, AND PARTICIPANTS: This quality improvement study including 439 LTC facilities in the US assessed antibiotic therapy data following a pragmatic quality-improvement program, which was implemented to assist facilities in establishing ASPs and with antibiotic decision-making. Training was conducted between December 2018 and November 2019. Data were analyzed from January 2019 to December 2019.
Fifteen webinars occurred over 12 months (December 2018 to November 2019), accompanied by additional tools, activities, posters, and pocket cards. All clinical staff were encouraged to participate.
The primary outcome was antibiotic starts per 1000 resident-days. Secondary outcomes included days of antibiotic therapy (DOT) per 1000 resident-days, the number of urine cultures per 1000 resident-days, and Clostridioides difficile laboratory-identified events per 10 000 resident-days. All outcomes compared data from the baseline (January-February 2019) to the completion of the program (November-December 2019). Generalized linear mixed models with random intercepts at the site level assessed changes over time.
Of a total 523 eligible LTC facilities, 439 (83.9%) completed the safety program. The mean difference for antibiotic starts from baseline to study completion per 1000 resident-days was -0.41 (95% CI, -0.76 to -0.07; P = .02), with fluoroquinolones showing the greatest decrease at -0.21 starts per 1000 resident-days (95% CI, -0.35 to -0.08; P = .002). The mean difference for antibiotic DOT per 1000 resident-days was not significant (-3.05; 95% CI, -6.34 to 0.23; P = .07). Reductions in antibiotic starts and use were greater in facilities with greater program engagement (as measured by webinar attendance). While antibiotic starts and DOT in these facilities decreased by 1.12 per 1000 resident-days (95% CI, -1.75 to -0.49; P < .001) and 9.97 per 1000 resident-days (95% CI, -15.4 to -4.6; P < .001), respectively, no significant reductions occurred in low engagement facilities. Urine cultures per 1000 resident-days decreased by 0.38 (95% CI, -0.61 to -0.15; P = .001). There was no significant change in facility-onset C difficile laboratory-identified events.
Participation in the AHRQ safety program was associated with the development of ASPs that actively engaged clinical staff in the decision-making processes around antibiotic prescriptions in participating LTC facilities. The reduction in antibiotic DOT and starts, which was more pronounced in more engaged facilities, indicates that implementation of this multifaceted program may support successful ASPs in LTC settings.
重要性:长期护理(LTC)中抗生素的过度使用很常见,这促使人们呼吁制定专门针对这些环境的抗生素管理计划(ASPs)。在 LTC 设施中建立强大且可持续的 ASP 的最佳方法尚不清楚。
目的:确定美国医疗保健研究与质量局(AHRQ)的安全计划是否可以改善抗生素的使用,这是一项建立专注于患者安全的 ASP 的教育计划,是否与减少 LTC 环境中的抗生素使用有关。
设计、地点和参与者:这项质量改进研究包括美国的 439 个 LTC 设施,在实施了一项务实的质量改进计划后评估了抗生素治疗数据,该计划旨在协助设施建立 ASP 并进行抗生素决策。培训于 2018 年 12 月至 2019 年 11 月进行。从 2019 年 1 月至 2019 年 12 月进行数据分析。
干预措施:在 12 个月(2018 年 12 月至 2019 年 11 月)期间进行了 15 次网络研讨会,同时还提供了其他工具、活动、海报和袖珍卡片。鼓励所有临床工作人员参加。
主要结果和措施:主要结果是每 1000 名居民-天的抗生素开始数。次要结果包括每 1000 名居民-天的抗生素治疗天数、每 1000 名居民-天的尿液培养数和每 10000 名居民-天的艰难梭菌实验室鉴定事件数。所有结果均将基线(2019 年 1 月至 2 月)与计划完成(2019 年 11 月至 12 月)的数据进行比较。在站点水平上使用随机截距的广义线性混合模型评估随时间的变化。
结果:在总共 523 个符合条件的 LTC 设施中,有 439 个(83.9%)完成了安全计划。每 1000 名居民-天的抗生素开始量从基线到研究完成的平均差异为-0.41(95%CI,-0.76 至 -0.07;P=0.02),氟喹诺酮类药物的降幅最大,为-0.21 个每 1000 名居民-天(95%CI,-0.35 至 -0.08;P=0.002)。每 1000 名居民-天的抗生素 DOT 平均差异无统计学意义(-3.05;95%CI,-6.34 至 0.23;P=0.07)。在参与度较高的设施中,抗生素开始和使用的减少幅度更大(以网络研讨会出席率衡量)。在这些设施中,抗生素开始和使用分别减少了 1.12 每 1000 名居民-天(95%CI,-1.75 至 -0.49;P<0.001)和 9.97 每 1000 名居民-天(95%CI,-15.4 至 -4.6;P<0.001),而在参与度较低的设施中则没有显著减少。每 1000 名居民-天的尿液培养数减少了 0.38(95%CI,-0.61 至 -0.15;P=0.001)。设施中艰难梭菌实验室鉴定事件的发生率没有显著变化。
结论和相关性:参与 AHRQ 安全计划与制定 ASP 有关,该计划使临床工作人员积极参与参与 LTC 设施中抗生素处方的决策过程。在更积极参与的设施中,抗生素 DOT 和开始量的减少更为明显,这表明实施这种多方面的计划可能支持 LTC 环境中成功的 ASP。